Explore

Search ClinicalTrials.gov

Find trials by condition, intervention, sponsor, or location. Filter by status, phase, and study type — or enter an NCT ID to jump straight to a trial.

Find trials by sponsor or company

Search by sponsors

RecruitingPhase IIIPhase III recruiting

StatusPhaseStudy typeSort

Results for “Pfizer”

A STUDY TO COMPARE THE PHARMACOKINETICS OF PF-06835919 IN PARTICIPANTS WITH AND WITHOUT HEPATIC IMPAIRMENTCompleted
NCT04193436Phase 1Updated Feb 16, 2024
Sponsor: Pfizer
Hepatic Impairment · Healthy Participants
Belgium, Czechia, Slovakia
Clinical Trial Investigating the Safety and Immunogenicity of GBS6 in Pregnant Women With and Without HIV (PREPARE)Unknown
NCT05832502Phase 2Updated Feb 16, 2024
Sponsor: St George's, University of London
Group B Streptococcal Infection
Uganda
Treatment Patterns and Clinical Outcomes Among Talazoparib-Treated Adults With HER2-Negative mBC With gBRCA1/2mCompleted
NCT05141708N/AUpdated Feb 16, 2024
Sponsor: Pfizer
Metastatic Breast Cancer · Breast Neoplasms
United States
Precedex Special Investigation (in Pediatric Patients)Completed
NCT04040439N/AUpdated Feb 16, 2024
Sponsor: Pfizer
Sedation
Japan
A Study Of Safety, Tolerability And Effectiveness Of Recifercept In Children With AchondroplasiaTerminated
NCT04638153Phase 2Updated Feb 15, 2024
Sponsor: Pfizer
Achondroplasia
United States, Australia, Belgium, Denmark, Italy +3 more
COVID-19 Vaccination and Breakthrough Infections Among Persons With Immunocompromising Conditions in the United StatesCompleted
NCT05020145N/AUpdated Feb 12, 2024
Sponsor: Pfizer
Immunocompromised · Immunosuppressed · Covid-19 · SARS-COV-2
United States
Dose, Safety, and Pathogenicity of a New Influenza B StrainUnknown
NCT06254820Phase 2Updated Feb 12, 2024
Sponsor: Hvivo
Influenza B
United Kingdom
Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown EtiologyCompleted
NCT03842163N/AUpdated Feb 12, 2024
Sponsor: Pfizer
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Australia, Austria, France, Italy, Portugal +5 more
PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial)Terminated
NCT05780541Phase 3Updated Feb 9, 2024
Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19
United States, Denmark
A Study to Compare the Experiences of Taking Daily Growth Hormone Injections to Weekly Ngenla in Children With Low Levels of Growth HormoneWithdrawn
NCT06113952N/AUpdated Feb 9, 2024
Sponsor: Pfizer
Pediatric Growth Hormone Deficiency
Continuation Study of Long-term Safety, Tolerability, Pharmacokinetics and Efficacy of Recifercept in AchondroplasiaTerminated
NCT05116046Phase 2Updated Feb 8, 2024
Sponsor: Pfizer
Achondroplasia
United States, Australia, Belgium, Denmark, Italy +2 more
Pediatric and Ambulatory Research in Infectious DiseasesRecruiting
NCT04471493N/AUpdated Feb 8, 2024
Sponsor: Association Clinique Thérapeutique Infantile du val de Marne
Otitis · Bronchiolitis · Influenza · Pharyngitis
France
Pneumonia and Empyema in Emergency Departments in ChildrenUnknown
NCT05274607N/AUpdated Feb 8, 2024
Sponsor: Association Clinique Thérapeutique Infantile du val de Marne
Pneumonia · Pleural Effusion
France
Efficacy And Safety Of Tofacitinib In Chinese Subjects With Active Psoriatic ArthritisCompleted
NCT03486457Phase 3Updated Feb 8, 2024
Sponsor: Pfizer
Psoriatic Arthritis
China
Effectiveness of Combination Varenicline and Oral Nicotine Replacement Therapy (COMBO)Terminated
NCT03722966Phase 2Updated Feb 6, 2024
Sponsor: University of Oklahoma
Smoking Cessation
United States
Multiple Escalating Oral Doses Study of PF-07081532 in Adult Participants With Type 2 Diabetes MellitusCompleted
NCT04305587Phase 1Updated Feb 5, 2024
Sponsor: Pfizer
Diabetes Mellitus Type 2
United States
Efficacy, Safety, and Tolerability of ATM-AVI in the Treatment of Serious Infection Due to MBL-producing Gram-negative BacteriaTerminated
NCT03580044Phase 3Updated Feb 2, 2024
Sponsor: Pfizer
Serious Bacterial Infection
United States, Argentina, China, Greece, India +7 more
Characterizing Skin Microbiome Change in Atopic DermatitisCompleted
NCT04800185EARLY_Phase 1Updated Feb 2, 2024
Sponsor: University of California, Irvine
Atopic Dermatitis · Atopic Dermatitis Eczema
United States
Tofacitinib Response in Ulcerative Colitis - a Real World Prospective Multi-center StudyTerminated
NCT03772145N/AUpdated Jan 31, 2024
Sponsor: University of North Carolina, Chapel Hill
Ulcerative Colitis
United States
Treatment Patterns And Clinical Outcomes Among Patients in Latin America Receiving First Line Palbociclib Combinations For HR+/HER2- Advanced/Metastatic Breast Cancer In Real World Settings.Completed
NCT05155566N/AUpdated Jan 26, 2024
Sponsor: Pfizer
Breast Cancer Metastatic
Argentina, United Kingdom
Study to Evaluate the Safety, Local and Systemic Tolerability, and Pharmacokinetics of Multiple-Dose Topical Administration of PF-07038124 in Japanese Healthy ParticipantsCompleted
NCT04863417Phase 1Updated Jan 25, 2024
Sponsor: Pfizer
Healthy
Japan
The Drug Rediscovery Protocol (DRUP Trial)Recruiting
NCT02925234Phase 2Updated Jan 24, 2024
Sponsor: The Netherlands Cancer Institute
Cancer · Tumors · Neoplasm · Neoplasia
Netherlands
Ketohexokinase Inhibition in NAFLDCompleted
NCT05463575Phase 2Updated Jan 24, 2024
Sponsor: Maastricht University Medical Center
NAFLD
Netherlands
A Phase II Study of Single Agent MEK162 in Patients With Advanced MelanomaCompleted
NCT01320085Phase 2Updated Jan 24, 2024
Sponsor: Pfizer
BRAF or NRAS Mutant Metastatic Melanoma
United States, Germany, Italy, Netherlands, Switzerland
Ketohexokinase Inhibition in Hereditary Fructose IntoleranceCompleted
NCT06089265Phase 2Updated Jan 24, 2024
Sponsor: Maastricht University Medical Center
HFI
Netherlands

Previous page Next page